Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes

Annals of the New York Academy of Sciences

Volumn 1037, Issue , 2004, Pages 1-9

  Bisikirska, Brygida C ^a   Herold, Kevan C ^a,b  

^a Columbia University ^*  (United States)

^b Department of Medicine ^*  (United States)

Author keywords

Anti CD3 monoclonal antibody; Autoimmunity; Regulatory T cells; Tolerance type 1 diabetes; Treatment

Indexed keywords

ALPHA INTERFERON; C PEPTIDE; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FC RECEPTOR; GAMMA INTERFERON; HEMOGLOBIN A1C; HUMAN MONOCLONAL ANTIBODY; INSULIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY CD3; OKT 3; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ADOLESCENT; ADULT; ANIMAL MODEL; ANTIGEN SPECIFICITY; AUTOIMMUNITY; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 14544289654     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1337.001     Document Type: Conference Paper

References (42)

1. DIABETES PREVENTION TRIAL-TYPE 1 DIABETES STUDY GROUP. 2002. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 346: 1685-1691.
2. CHATENOUD, L., E. THERVET, J. PRIMO & J.F. BACH. 1994. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. USA 91: 123-127.
3. CHATENOUD, L., J. PRIMO & J.F. BACH. 1997. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. 158: 2947-2954.
4. CHATENOUD, L. 1993. OKT3-induced cytokine-release syndrome: prevention effect of anti-tumor necrosis factor monoclonal antibody. Transplant. Proc. 25: 47-51.
5. HIRSCH, R., J.A. BLUESTONE, C.V. BARE & R.E. GRESS. 1991. Advantages of F(ab′)2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice. Transplant. Proc. 23: 270-271.
6. HIRSCH, R., J.A. BLUESTONE, L. DENENNO & R.E. GRESS. 1990. Anti-CD3 F(ab′)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 49: 1117-1123.
7. HEROLD, K.C. et al. 1992. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 41: 385-391.
8. BOLT, S. et al. 1993. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol. 23: 403-411.
9. ALEGRE, M.L. et al. 1992. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J. Immunol. 148: 3461-3468.
10. SMITH, J.A. & J.A. BLUESTONE. 1997. T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs. Curr. Opin. Immunol. 9: 648-654.
11. Smith, J.A., Q. Tang & J.A. Bluestone. 1998. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J. Immunol. 160: 4841-4849.
12. SMITH, J.A., J.Y. Tso, M.R. CLARK, et al. 1997. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J. Exp. Med. 185: 1413-1422.
13. RABINOVITCH, A. 1998. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab. Rev. 14: 129-151.
14. XU, D. et al. 2000. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell. Immunol. 200: 16-26.
15. HEROLD, K.C. et al. 2003. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J. Clin. Invest. 111: 409-418.
16. WOODLE, E.S. et al. 1999. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68: 608-616.
17. HEROLD, K.C. et al. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346: 1692-1698.
18. MATHIS, D. & C. BENOIST. 2004. Back to central tolerance. Immunity 20: 509-516.
19. ANDRE, I. et al. 1996. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc. Natl. Acad. Sci. USA 93: 2260-2263.
20. BACH, J.F. & L. CHATENOUD. 2001. Tolerance to islet autoantigens in type 1 diabetes. Annu. Rev. Immunol. 19: 131-161.
21. SAKAGUCHI, S. 2003. The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery. J. Clin. Invest. 112: 1310-1312.
22. SAKAGUCHI, S., N. SAKAGUCHI, M. ASANO, et al. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155: 1151-1164.
23. SALOMON, B. et al. 2000. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431-440.
24. TAKAHASHI, T. et al. 1998. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10: 1969-1980.
25. THORNTON, A.M. & E.M. SHEVACH. 1998. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188: 287-296.
26. FONTENOT, J.D., M.A. GAVIN & A.Y. RUDENSKY. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4: 330-336.
27. KHATTRI, R., T. COX, S.A. YASAYKO & F. RAMSDELL. 2003. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 4: 337-342.
28. RAMSDELL, F. 2003. Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity 19: 165-168.
29. SCHUBERT, L.A., E. JEFFERY, Y. ZHANG, et al. 2001. (FOXP3) acts as a repressor of transcription and regulates T cell activation. J. Biol. Chem. 276: 37672-37679.
30. WALKER, M.R. et al. 2003. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J. Clin. Invest. 112: 1437-1443.
31. APOSTOLOU, I. & H. VON BOEHMER. 2004. In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. 199: 1401-1408.
32. RONCAROLO, M.G., R. BACCHETTA, C. BORDIGNON, et al. 2001. Type 1 T regulatory cells. Immunol. Rev. 182: 68-79.
33. BELGHITH, M. et al. 2003. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9: 1202-1208.
34. HERING, B.J. et al. 2004. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am. J. Transplant. 4: 390-401.
35. GROUX, H. et al. 1997. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389: 737-742.
36. O'GARRA, A. & F.J. BARRAT. 2003. In vitro generation of IL-10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by Th1- and Th2-inducing cytokines. Immunol. Lett. 85: 135-139.
37. FOULDS, K.E. et al. 2002. Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J. Immunol. 168: 1528-1532.
38. CHANG, C.C. et al. 2002. Tolerization of dendritic cells by TS cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat. Immunol. 3: 237-243.
39. SUCIU-FOCA, N., J.S. MANAVALAN & R. CORTESINI. 2003. Generation and function of antigen-specific suppressor and regulatory T cells. Transplant. Immunol. 11: 235-244.
40. COSMI, L. et al. 2003. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood 102: 4107-4114.
41. ANNUNZIATO, F. et al. 2002. Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. J. Exp. Med. 196: 379-387.
42. SLOAN-LANCASTER, J. & P.M. ALLEN. 1996. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu. Rev. Immunol. 14: 1-27.